Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 275

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 275
---
 business. In addition, APx valued that OmnigenicsAI was not a startup per se but a spin -offfrom two parent companies: Bioceres S.A., an established agricultural solutions company, and CIBIC laboratories, a biotechnology in the clinical diagnostics industry based in Argentina, as described above. On July 3, 2023, the Sponsor, the Parent and Theo entered into the Heritas LOI. The execution version was substantially similar to the previously circulated draft, provided that it contemplated Sponsor act as the sponsor for the transaction for the reasons described above. Parent and Theo are both affiliates of Bioceres, and direct or indirect shareholders of OmnigenicsAI and Heritas Argentina, controlling such entities. While the Heritas LOI refers to the acquisition of Parent and Theo, through subsequent structuring discussions, the parties determined that the appropriate legal target would be OmnigenicsAI. On July 25, 2023, OmnigenicsAI management had a meeting with its board of directors to discuss the MultiplAI transaction, the repercussions and benefits of the deal with OmnigenicsAI and the strategy to go public through a business combination transaction. During this meeting, high level terms and conditions of the LOI were aligned to execute the LOI with MultiplAI (the “MultiplAI LOI”). On July 31, 2023, OmnigenicsAI’s Board of Directors met with MultiplAI to discuss these terms and conditions, specifically the valuation of both companies, given that OmnigenicsAI was negotiating a $300 million valuation with the Sponsor for the de -SPACtransaction. In parallel, negotiations occurred via different channels during the following weeks, specifically regarding representations and warranties and expenses. On August 9, 2023, Mr. Calmet met with the board of directors of the Parent to discuss the final details of the MultiplAI LOI prior to its signing. On August 15, 2023, the Parent entered into the MultiplAI LOI. The MultiplAI LOI establishes that the Parent would acquire 100% of the outstanding equity and equity equivalents of MultiplAI (including options, warrants or other securities that have the right to acquire or convert into equity securities of MultiplAI), or all MultiplAI’s business, in exchange for a fully diluted pre -moneytotal enterprise value target of MultiplAI of $40 million, taking into account net zero cash and debt. On August 17, 2023, Mr. Brans